<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028975</url>
  </required_header>
  <id_info>
    <org_study_id>VERGES 2009</org_study_id>
    <nct_id>NCT02028975</nct_id>
  </id_info>
  <brief_title>Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.</brief_title>
  <official_title>Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      Animal studies have shown that stimulation of the lingual lipid-receptor, CD 36, is&#xD;
      accompanied by the rapid secretion of hormones in the digestive tract (incretines). We aim to&#xD;
      determine in healthy humans whether the orosensory perception of fatty acids is followed by a&#xD;
      modification in plasma levels of digestive tract hormones (cholecystokinin, GIP, GLP-1,&#xD;
      secretin, pancreatic peptide, peptide YY, insulin) and metabolic markers from adipose tissue&#xD;
      (leptin, ghrelin, adiponectin).&#xD;
&#xD;
      We also aim to determine whether the hormonal response induced by orosensory stimulation by&#xD;
      lipids is modified:&#xD;
&#xD;
        -  in patients with type 2 diabetes&#xD;
&#xD;
        -  in obese non-diabetic patients We expect to show an increase in biological markers&#xD;
           biological, and more particularly in certain digestive hormones such as Pancreatic&#xD;
           polypeptide, GIP, GLP-1â€¦after stimulation of the lingual lipid receptor, CD36. We will&#xD;
           also determine whether or not this response is modified in patients with type 2 diabetes&#xD;
           and in obese non-diabetic patients.&#xD;
&#xD;
      We also wish to measure the subjects' gustatory detection threshold for a fatty acid&#xD;
      (linoleic acid), and to determine whether there is a relationship between the orosensory&#xD;
      perception threshold for linoleic acid and the physiological status of the subjects. In order&#xD;
      to achieve this, the thresholds for healthy subjects will be compared with thresholds for&#xD;
      obese and diabetic subjects. Expected results: the threshold of detection for linoleic acid&#xD;
      in healthy subjects will be lower than that in obese or diabetic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of biological markers of orosensorielle perception fatty acids</measure>
    <time_frame>Change from baseline at 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the detection threshold for linoleic acid</measure>
    <time_frame>baselines</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Type 2 Diabetes or Obesity Without Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measure the threshold of detection for linoleic acid</intervention_name>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral stimulation tests</intervention_name>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Venous blood samples</intervention_name>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples for genetic studies (ancillary study)</intervention_name>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  persons who have provided written consent&#xD;
&#xD;
          -  Healthy volunteers:&#xD;
&#xD;
          -  Men &gt; 18 years&#xD;
&#xD;
          -  19 &lt;BMI &lt; 25 kg.m-2&#xD;
&#xD;
          -  Fasting triglyceridemia &lt; 1.50 g/l&#xD;
&#xD;
          -  Fasting glycemia &lt; 1.10 g/l&#xD;
&#xD;
          -  Without regular medical treatment&#xD;
&#xD;
          -  Patients with type-2 diabetes:&#xD;
&#xD;
          -  Men &gt;18 years&#xD;
&#xD;
          -  type 2 diabetes (fasting glycemia &gt; 7 mmol/l at the diagnosis) treated with diet or&#xD;
             diet + oral antidiabetics (metformin, and/or insulinsecretion agents [hypoglycemic&#xD;
             sulphonamides, or glinides] and/or glitazones and/or acarbose)&#xD;
&#xD;
          -  Stable oral antidiabetic treatment for 3 months&#xD;
&#xD;
          -  Obese non-diabetic patients:&#xD;
&#xD;
          -  Men &gt; 18 years&#xD;
&#xD;
          -  BMI 30 kg.m-2&#xD;
&#xD;
          -  Fasting glycemia &lt; 1.10 g/l&#xD;
&#xD;
          -  HbA1c &lt; 6.0%&#xD;
&#xD;
          -  Absence of treatment with hypoglycemic agents (including benfluorex)&#xD;
&#xD;
          -  Absence of medical treatment for obesity&#xD;
&#xD;
          -  Absence of a history of surgery for obesity (band, by-pass) or gastric stimulator&#xD;
             (type Tantalus)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons not covered by the national health insurance&#xD;
&#xD;
          -  Smokers, or smoking cessation within the 3 months preceding inclusion&#xD;
&#xD;
          -  Persons with eating disorders:&#xD;
&#xD;
          -  Severe digestive disease (enteropathy with absorption disorders, inflammatory&#xD;
             digestive disease)&#xD;
&#xD;
          -  Pancreatic insufficiency&#xD;
&#xD;
          -  History of pancreas surgery&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Treatment with proton pump inhibitors, insulin, GLP-1 analogues, DPP-4 inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Bruno VERGES</last_name>
    <phone>3 80 29 34 53</phone>
    <phone_ext>+33</phone_ext>
    <email>bruno.verges@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle ROBIN</last_name>
      <phone>3 80 29 33 32</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.simoneau-robin@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

